期刊文献+

Fibroscan无创性评估慢性乙型肝炎肝纤维化的应用价值 被引量:4

Application value of fibroscan for liver fibrosis in patients with chronic hepatitis B
下载PDF
导出
摘要 目的探讨肝脏瞬时弹性波扫描仪(Fibroscan,FS)对慢性乙型肝炎肝脏纤维化的应用价值。方法应用FS对105名慢性乙型肝炎患者进行肝穿刺前肝脏硬度测量值(LSM)的测定,采用肝穿刺活组织病理诊断技术进行肝纤维化分期(S),并将肝穿刺组织学检查作为判断肝纤维化的金标准绘制FS工作特征曲线,算出ROC曲线下面积(AUC)。结果肝脏硬度值和肝组织纤维化分期呈显著正相关(r=0.768,P<0.01)。肝活检纤维化分期≥S1、≥S2、≥S3、S4的AUC分别为0.886、0.902、0.941、0.957,以灵敏度和特异度之和的最大值选定的诊断界值(cut-off值)分别为5.11、7.12、11.25、15.76kPa。结论 FS无创性评估肝纤维化为一种有效可行的方法,有较好的临床应用价值。 Objective To investigate the application value of Fibroscan for liver fibrosis in patients with chronic hepatitis B (CHB) .Methods Liver stiffness measurement (LSM)of 105 patients with CHB were measured by Fibroscan before the liv‐er biopsy .Pathological diagnosis of liver biopsy was adopted to perform the liver fibrosis stage (S) .With the liver biopsy as the gold standard for judging liver fibrosis , receiver operating characteristic (ROC) curves were drawed ,and the area under the ROC curves (AUC) was calculated .Results There was a significantly positive correlation between liver stiffness measurement and liver fibrosis stage (r=0.768 , P〈0.01) .The AUC of liver biopsy fibrosis stage ≥S1、 ≥S2、 ≥S3、S4 were 0.886、0.902、0.941 and 0.957 ,respectively .The cut‐off values of LSM were 5.11、7.12、11.25 and 15.76 kPa by maximizing the sum of sensitivity and specificity . Conclusion Noninvasive assessment of liver fibrosis by using FS is an effective way ,and w hich has a good value in clinical application .
出处 《福建医药杂志》 CAS 2015年第5期97-99,共3页 Fujian Medical Journal
关键词 肝炎 乙型 慢性 肝硬化 活组织检查 瞬时弹性波扫描仪 hepatitis B,chronic liver cirrhosis liver biopsy fibroscan
  • 相关文献

参考文献2

二级参考文献34

  • 1Jin B, Alter HJ, Zhang ZC, et al. Reversibility of experimental rabbit liver cirrhosis by portal collagenese administration[J]. Lab Invest, 2005, 85(8): 992-1002.
  • 2Benyon RC, Iredale JP. Is liver fibrosis reversible[J]? Gut, 2000, 46(4): 443-446.
  • 3Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible[J]? N Engl J Med, 2001, 344(6): 452-453.
  • 4Okazaki I, Watanabe T, Hozawa S, et al. Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery[J]. Keio J Med, 2001, 50(2):58-65.
  • 5Watanabe T, Niioka M, Hozawa S, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride[J]. J Hepatol, 2000, 33(2):224-235.
  • 6Hironaka K, Sakaida I, Matsumura Y, et al. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis[J]. Biochem Biophys Res Commun, 2000, 267(1):290-295.
  • 7Perez Tamayo R, Montfort I, Gonzalez E. Collagenolytic activity in experimental cirrhosis of the liver[J]. Exp Mol Pathol, 1987, 47(3): 300-308.
  • 8Kossakowska AE, Edwards DR, Lee SS, et al. Altered balance between matrix metalloproteinase and their inhibitors in experimental biliary fibrosis[J]. Am J Pathol, 1998, 153(6): 1895-1902.
  • 9Iredale JP, Benyon RC, Arthur MJP, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expre-ssion is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis[J]. Hepatology, 1996, 24(1): 176-184.
  • 10Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinase 1 and 2 is increased in fibrotic human liver[J]. Gastroenterology, 1996, 110(3): 821-831.

共引文献14019

同被引文献36

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部